Scientists uncover why cancer patients with ARID1A gene mutations are more likely to respond to immunotherapy, discovering ARID1A mutations invite cancer-fighting immune cells into tumors by triggering an antiviral-like response. Their findings could help improve cancer care and drug development for many cancer types, including endometrial, ovarian, colon, gastric, liver, and pancreatic cancers.
